Introduction: Statins are cholesterol-lowering drugs that are widely used to prevent and treat atherosclerotic cardiovascular disease. It was found that statins can be associated with the occurrence of prostate cancer. However, no consensus has been concluded. Materials and Methods: In the present study, we provide a refined meta-analysis on the association between statins and prostate cancers. Our objective is to offer a congruent recognition of the impact of statins on prostate cancer. Results: Our refined analysis has included seven previous publications from the years 2005 to 2010. Conclusions: Based on the results, we concluded that there were associations for statin usage in preventing prostate cancer (OR 1.195, 95% CI 1.018-1.403, p = 0.029). Different from previous meta-analyses, our positive conclusion is primarily based on the recent new published literature, which supported the efficiency of statin use to control prostate cancer. More specific efforts for excluding the influence of other factors are crucial in further assessment of the efficiency of statin use.

Keywords:
Statins, Prostate cancer, Meta-analysis
1.
Murtola TJ, Visakorpi T, Lahtela J, Syvala H, Tammela TLJ: Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol 2007;5:376-387.
2.
Bonovas S, Filioussi K, Sitaras NM: Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008;123:899-904.
3.
Karp I, Behlouli H, Lelorier J, Pilote L: Statins and cancer risk. Am J Med 2008;121:302-309.
4.
Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT, Women's Health Initiative Research Group: Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700-708.
5.
Shannon J, Tewoderos S, Garzotto M, et al: Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-325.
6.
Browning DR, Martin RM: Statins and risk of cancer: a systematic review and meta-analysis. Int J Cancer 2007;120:833-843.
7.
Bonovas S, Filioussi K, Tsavaris N, Sitaaras NM: Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-4817.
8.
Hamilton RJ, Freedland SJ: Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 2008;18:333-339.
9.
Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825.
10.
Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL: Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168:250-260.
11.
Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J: Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010;126:279-284.
12.
Taylor ML, Wells BJ, Smolak MJ: Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 2008;17:259-268.
13.
Colli JL, Amling CL: High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. Urol Oncol 2009;27:170-173.
14.
Flick ED, Habel LA, Chan KA, et al: Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-2225.
15.
Boudreau DM, Yu O, Buist DS, Miglioretti DL: Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008;19:767-774.
16.
Murtola TJ: Statin use is associated with improved prostate cancer survival: is it time for a clinical trial? Expert Rev Anticancer Ther 2010;10:1563-1567.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.